Dec 19 Ionis Pharmaceuticals Inc said on Monday its metabolic disorder drug for severe hypertriglyceridemia, characterized by elevated levels of a type of fat in the blood, met the main goal in a late-stage study.
The drug, volanesorsen, brought about a statistically significant 71.2 percent mean reduction in triglycerides after 13 weeks of treatment, compared with 0.9 percent in those who got the placebo, the company said.
Patients in the trial had two rare metabolic disorders: familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy (FPL). (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Martina D'Couto)
UPDATE 1-Trump administration drafts plan to raise asylum bar, speed deportations
(Adds proposed changes to deportation guidelines) By Julia Edwards Ainsley WASHINGTON, Feb 18 The Department of Homeland Security has prepared new guidance for immigration agents aimed at speeding up deportations by denying asylum claims earlier in the process. The new guidelines, contained in a draft memo dated February 17 but not yet sent to field offices, directs agents to only pass applicants who have a good chance of ultimately getting asylum, but does not give spe
UPDATE 4-SpaceX launches rocket from historic NASA pad in Florida
CAPE CANAVERAL, Fla., Feb 19 A SpaceX Falcon rocket blasted off on Sunday from a Florida launch pad once used to send NASA astronauts to the moon, a step forward for billionaire entrepreneur Elon Musk and his company's goal of ferrying astronauts to the International Space Station. The 229-foot tall (70-meter) Falcon 9 soared off a seaside launch pad at the Kennedy Space Center at 9:39 a.m. EST (1439 GMT) carrying a Dragon cargo ship that holds supplies and science experiments for